Trifluridine/tipiracil for the treatment of metastatic gastric cancer

References

• International Agency for Research on Cancer. Globocan 2018: stomach. [cited 2018 Oct 4]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
   Google Scholar
• Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (version 4). Gastric Cancer. 2017;20:1–19.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Gastric cancer (version 2.2018). [cited 2018 Aug 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
   Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–3976.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:420–435.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Bang Y-J, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37(18_suppl):LBA4007-LBA4007. Abstract LBA4007.
   Web of Science ®Google Scholar
• Emura T, Nakagawa F, Fujioka A, et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med. 2004;13:249–255.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Kazuno H, Emura T, et al. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000;17:277–283.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Sakamoto K, Okabe H, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014;32:2319–2326.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Suzuki N, Emura T, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2ʹ-deoxyribonucleosides. Biochem Pharmacol. 2000;59:1227–1236.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919.
   PubMed Web of Science ®Google Scholar
• Bando H, Doi T, Muro K, et al. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer. 2016;62:46–53.
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437–1448.
   PubMed Web of Science ®Google Scholar
• Taiho Oncology Inc. LONSURF (trifluridine and tipiracil) tablets for oral use: uSprescribinginfomation. 2015 [cited 2016 Aug 9]. Available from: https://www.taihooncology.com/us/prescribing-information.pdf
   Google Scholar
• European Medicines Agency. Lonsurf (trifluridine/tipiracil): summary of product characteristics. 2016 [cited 2016 Jun 13]. Available from: http://www.ema.europa.eu/
   Google Scholar
• Matsuoka K, Iimori M, Niimi S, et al. Trifluridine induces p53 dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther. 2015;14(4):1004–1013.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Komoto I, Oka H, et al. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Cancer Chemother Pharmacol. 2015;76(2):325–333.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Nakagawa F, Kobunai T, et al. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget. 2018;9:13438–13450.
   PubMedGoogle Scholar
• Doi T, Ohtsu A, Yoshino T, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107:429–434.
   PubMed Web of Science ®Google Scholar
• Sun W, Rosen LS, Rasco DW, et al. An open-label, randomized, parallel-group study of the pharmacokinetics of trifluridine as a component of TAS-102 versus FTD alone [abstract no. 751]. J Clin Oncol. 2016;34(Suppl4):751.
   Google Scholar
• Overman MJ, Kopetz S, Varadhachary G, et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008;26:794–799.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Varadhachary G, Kopetz S, et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008;26:445e54.
   Web of Science ®Google Scholar
• Peters GJ. Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv Med Oncol. 2015;7:340–356.
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Hosaka H, et al. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): subgroup analysis from TAGS. J Clin Oncol. 2019 May 20;37(15_suppl):4037.
   Web of Science ®Google Scholar
• Wasat Mansoor W, Arkenau HT, ALSINA M, et al. Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): subgroup analysis from TAGS. J Clin Oncol. 2019 May 20;37(15_suppl):4038.
   Web of Science ®Google Scholar
• Ilson DH, Prokharau A, Arkenau HT, et al. Efficacy and safety of trifluridine/tipiracil in patients with metastatic gastric cancer with prior gastrectomy: results from a phase 3 study (TAGS). J Clin Oncol. 2019 February 01;37(4_suppl):3.
   Web of Science ®Google Scholar
• Tsukihara H, Nakagawa F, Sakamoto K, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33:2135–2142.
   PubMed Web of Science ®Google Scholar
• Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicenter, phase 1/2 study. Lancet Oncol. 2017;18:1172–1181.
   PubMed Web of Science ®Google Scholar
• Lesniewski-Kmak K, Moiseenko V, Saunders M, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. Ann Oncol. 2018;29:mdy149–021.
   Web of Science ®Google Scholar
• Pfeiffer P, Yilmaz M, Möller S, et al. Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC). J Clin Oncol. 2019;37:637.
   Web of Science ®Google Scholar
• Nukatsuka M, Nakagawa F, Saito H, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35:1437–1445.
   PubMed Web of Science ®Google Scholar
• Doi T, Yoshino T, Fuse N, et al. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs. 2015;33:1068–1077.
   PubMed Web of Science ®Google Scholar